94 related articles for article (PubMed ID: 33340853)
1. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study).
Nakayama G; Takano N; Taniguchi H; Ishigure K; Yokoyama H; Teramoto H; Hashimoto R; Sakai M; Ishiyama A; Kinoshita T; Hayashi N; Nakamura M; Hattori N; Sato Y; Umeda S; Uehara K; Aiba T; Sonohara F; Hayashi M; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Murotani K; Ando M; Ando Y; Muro K; Kodera Y
Eur J Cancer; 2021 Feb; 144():61-71. PubMed ID: 33340853
[TBL] [Abstract][Full Text] [Related]
2. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
André T; Meyerhardt J; Iveson T; Sobrero A; Yoshino T; Souglakos I; Grothey A; Niedzwiecki D; Saunders M; Labianca R; Yamanaka T; Boukovinas I; Vernerey D; Meyers J; Harkin A; Torri V; Oki E; Georgoulias V; Taieb J; Shields A; Shi Q
Lancet Oncol; 2020 Dec; 21(12):1620-1629. PubMed ID: 33271092
[TBL] [Abstract][Full Text] [Related]
3. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Grothey A; Sobrero AF; Shields AF; Yoshino T; Paul J; Taieb J; Souglakos J; Shi Q; Kerr R; Labianca R; Meyerhardt JA; Vernerey D; Yamanaka T; Boukovinas I; Meyers JP; Renfro LA; Niedzwiecki D; Watanabe T; Torri V; Saunders M; Sargent DJ; Andre T; Iveson T
N Engl J Med; 2018 Mar; 378(13):1177-1188. PubMed ID: 29590544
[TBL] [Abstract][Full Text] [Related]
4. Real-world tolerance and outcomes of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer-Does dose intensity matter?
Yoon R; Wilkinson K; Gabriel G; Kadaan N; Roberts T; Lim S; Asghari R; Lee CS; Chua W; Ng W
Asia Pac J Clin Oncol; 2024 Feb; 20(1):63-70. PubMed ID: 37211922
[TBL] [Abstract][Full Text] [Related]
5. Study protocol of short-course radiotherapy combined with CAPOX and PD-1 inhibitor for locally advanced colon cancer: a randomised, prospective, multicentre, phase II trial (TORCH-C).
Zhang H; Li Y; Xia F; Sun Y; Shen L; Wan J; Chen Y; Wang Y; Zhou M; Wu R; Zhou S; Wang Y; Liu F; Cai S; Zhang Z
BMJ Open; 2024 Feb; 14(2):e079442. PubMed ID: 38309748
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically.
Bardakci M; Demirtas Esmer D; Hafizoglu E; Yaslikaya S; Genc TB; Ozcelik M; Erdat EC; Hendem E; Buyukbayram ME; Alaca Topcu Z; Kalkan Z; Yildirim N; Celebi A; Ergun Y; Paydas S; Tatli AM; Karakas H; Koseci T; Sendur MAN
Oncology; 2023; 101(11):723-729. PubMed ID: 37379817
[TBL] [Abstract][Full Text] [Related]
7. Comparison of adjuvant capecitabine plus oxaliplatin (CAPOX) versus S-1 after gastrectomy: a population-based cohort study using a nationwide claims database.
Maeng CH; Kim H; Kim M
Sci Rep; 2023 Oct; 13(1):17154. PubMed ID: 37821636
[TBL] [Abstract][Full Text] [Related]
8. Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.
Iveson TJ; Sobrero AF; Yoshino T; Souglakos I; Ou FS; Meyers JP; Shi Q; Grothey A; Saunders MP; Labianca R; Yamanaka T; Boukovinas I; Hollander NH; Galli F; Yamazaki K; Georgoulias V; Kerr R; Oki E; Lonardi S; Harkin A; Rosati G; Paul J
J Clin Oncol; 2021 Feb; 39(6):631-641. PubMed ID: 33439695
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Gallois C; Shi Q; Meyers JP; Iveson T; Alberts SR; de Gramont A; Sobrero AF; Haller DG; Oki E; Shields AF; Goldberg RM; Kerr R; Lonardi S; Yothers G; Kelly C; Boukovinas I; Labianca R; Sinicrope FA; Souglakos I; Yoshino T; Meyerhardt JA; André T; Papamichael D; Taieb J
J Clin Oncol; 2023 Feb; 41(4):803-815. PubMed ID: 36306483
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial.
Hu H; Zhang J; Li Y; Wang X; Wang Z; Wang H; Kang L; Liu P; Lan P; Wu X; Zhen Y; Pei H; Huang Z; Zhang H; Chen W; Zeng Y; Lai J; Wei H; Huang X; Chen J; Chen J; Tao K; Xu Q; Peng X; Liang J; Cai G; Ding K; Ding Z; Hu M; Zhang W; Tang B; Hong C; Cao J; Huang Z; Cao W; Li F; Wang X; Wang C; Huang Y; Zhao Y; Cai Y; Ling J; Xie X; Wu Z; Shi L; Ling L; Liu H; Wang J; Huang M; Deng Y;
J Clin Oncol; 2024 Apr; ():JCO2301889. PubMed ID: 38564700
[TBL] [Abstract][Full Text] [Related]
11. Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.
Okamoto K; Nozawa H; Emoto S; Murono K; Sasaki K; Ishihara S
Support Care Cancer; 2023 Oct; 31(12):660. PubMed ID: 37897532
[TBL] [Abstract][Full Text] [Related]
12. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
Lee S; Ma C; Shi Q; Kumar P; Couture F; Kuebler P; Krishnamurthi S; Lewis D; Tan B; Goldberg RM; Venook A; Blanke C; O'Reilly EM; Shields AF; Meyerhardt JA
J Clin Oncol; 2023 Feb; 41(5):1079-1091. PubMed ID: 36367997
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin‑induced changes in splenic volume and liver fibrosis indices: retrospective analyses of colon cancer patients receiving adjuvant chemotherapy.
Bir Yücel K; Kilic ACK; Sütcüoglu O; Yazıcı O; Kilic K; Savaş G; Uner A; Günel N; Özet A; Özdemir N
J Chemother; 2024 May; 36(3):249-257. PubMed ID: 37578138
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy in stage II-III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX.
Ramaswamy A; Kothari R; Desouza A; Gupta T; Bairwa S; Kapoor A; Kumar A; Ventrapati P; Ramadwar M; Mandavkar S; Chavan N; Saklani A; Ostwal V
South Asian J Cancer; 2019; 8(3):160-165. PubMed ID: 31489288
[TBL] [Abstract][Full Text] [Related]
15. Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer: YCOG1402 (SOAP trial).
Suwa Y; Watanabe J; Suwa H; Ozawa M; Momiyama M; Ishibe A; Nagamine K; Yamagishi S; Ota M; Fukushima T; Sekido H; Saigusa Y; Endo I
Ann Gastroenterol Surg; 2023 Nov; 7(6):922-931. PubMed ID: 37927922
[TBL] [Abstract][Full Text] [Related]
16. Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer.
Yu IS; Pereira AAL; Lee M; Korphaisarn K; Marshall J; Segelov E; O'Callaghan C; Lim HJ; Kopetz S; Loree JM
Oncologist; 2020 Mar; 25(3):229-234. PubMed ID: 32162828
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of the Leftover Capecitabine Tablets in Adjuvant CAPOX Chemotherapy for Gastric Cancer].
Kimura Y; Kawakami K; Nakamura M; Yokokawa T; Shimizu H; Kobayashi K; Aoyama T; Suzuki W; Hatori M; Suzuki K; Takahari D; Ogura M; Chin K; Nakayama I; Wakatsuki T; Yamaguchi K; Yamaguchi M
Yakugaku Zasshi; 2023; 143(12):1075-1081. PubMed ID: 38044112
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors for Thrombocytopenia Induced by Capecitabine Plus Oxaliplatin Therapy in Patients With Colorectal Cancer.
Kato N; Nakai T; Kodama S; Koyama S; Nakane S; Wada Y; Oda H; Katayama H; Mase H; Miyagawa Y; Miyazaki M; Yamada S; Yamada K
In Vivo; 2024; 38(3):1243-1252. PubMed ID: 38688620
[TBL] [Abstract][Full Text] [Related]
19. The Optimal Duration of Adjuvant Chemotherapy in Colon Cancer.
Collienne M; Arnold D
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899406
[TBL] [Abstract][Full Text] [Related]
20. Estimating Treatment Effect of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer Using Bayesian Networks.
Sieswerda M; van Rossum R; Bermejo I; Geleijnse G; Aben K; van Erning F; de Hingh I; Lemmens V; Dekker A; Verbeek X
JCO Clin Cancer Inform; 2023 Sep; 7():e2300080. PubMed ID: 37748112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
